Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Harry VanDusen is active.

Publication


Featured researches published by Harry VanDusen.


JAMA | 2016

Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.

Areej El-Jawahri; Thomas W. LeBlanc; Harry VanDusen; Lara Traeger; Joseph A. Greer; William F. Pirl; Vicki A. Jackson; Jason Telles; Alison Rhodes; Thomas R. Spitzer; Steven L. McAfee; Yi-Bin Chen; Stephanie S. Lee; Jennifer S. Temel

Importance During hospitalization for hematopoietic stem cell transplantation (HCT), patients receive high-dose chemotherapy before transplantation and experience significant physical and psychological symptoms and poor quality of life (QOL). Objective To assess the effect of inpatient palliative care on patient- and caregiver-reported outcomes during hospitalization for HCT and 3 months after transplantation. Design, Setting, and Participants Nonblinded randomized clinical trial among 160 adults with hematologic malignancies undergoing autologous/allogeneic HCT and their caregivers (n = 94). The study was conducted from August 2014 to January 2016 in a Boston hospital; follow-up was completed in May 2016. Interventions Patients assigned to the intervention (n=81) were seen by palliative care clinicians at least twice a week during HCT hospitalization; the palliative intervention was focused on management of physical and psychological symptoms. Patients assigned to standard transplant care (n=79) could be seen by palliative care clinicians on request. Main Outcomes and Measures Primary: change in patient QOL from baseline to week 2; secondary: patient-assessed mood, fatigue, and symptom burden scores at baseline, 2 weeks, and 3 months after HCT and caregiver-assessed QOL and mood at baseline and 2 weeks after HCT. Results Among 160 enrolled patients (mean age, 60 [SD, 13.3] years; 91 women [56.9%]; median hospital stay, 21 days) and 94 caregivers, 157 (98.1%) and 89 (94.7%), respectively, completed 2-week follow-up, and 149 patients (93.1%) completed 3-month follow-up. Patients in the intervention group reported a smaller decrease in QOL from baseline to week 2 (mean baseline score, 110.26; week 2 score, 95.46; mean change, -14.72) compared with patients in the control group (mean baseline score, 106.83; week 2 score, 85.42; mean change, -21.54; difference between groups, -6.82; 95% CI, -13.48 to -0.16; P = .045). Among the secondary outcomes, from baseline to week 2, patients in the intervention group vs those in the control group had less increase in depression (mean, 2.43 vs 3.94; mean difference, 1.52; 95% CI, 0.23-2.81; P = .02), lower anxiety (mean, -0.80 vs 1.12; mean difference, 1.92; 95% CI, 0.83-3.01; P < .001), no difference in fatigue (mean, -10.30 vs -13.65; mean difference, -3.34; 95% CI, -7.25 to 0.56; P = .09), and less increase in symptom burden (mean, 17.35 vs 23.14; mean difference, 5.80; 95% CI, 0.49-11.10; P = .03). At 3 months after HCT, intervention patients vs control patients had higher QOL scores (mean, 112.00 vs 106.66; mean difference, 5.34; 95% CI, 0.04-10.65; P = .048) and less depression symptoms (mean, 3.49 vs 5.19; mean difference, -1.70; 95% CI, -2.75 to -0.65; P = .002) but no significant differences in anxiety, fatigue, or symptom burden. From baseline to week 2 after HCT, caregivers of patients in the intervention group vs caregivers of patients in the control group reported no significant differences in QOL or anxiety but had a smaller increase in depression (mean, 0.25 vs 1.80; mean difference, 1.55; 95% CI, 0.14-2.96; P = .03). Conclusions and Relevance Among adults at a single institution undergoing HCT for hematologic malignancy, the use of inpatient palliative care compared with standard transplant care resulted in a smaller decrease in QOL 2 weeks after transplantation. Further research is needed for replication and to assess longer-term outcomes and cost implications. Trial Registration clinicaltrials.gov Identifier: NCT02207322.


Cancer | 2015

Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation

Areej El-Jawahri; Lara Traeger; Kailyn Kuzmuk; Justin Eusebio; Harry VanDusen; Jennifer A. Shin; Tanya Keenan; Emily R. Gallagher; Joseph A. Greer; William F. Pirl; Vicki A. Jackson; Karen K. Ballen; Thomas R. Spitzer; Timothy A. Graubert; Steven L. McAfee; Bimalangshu R. Dey; Yi-Bin Chen; Jennifer S. Temel

We conducted a study to investigate the impact of hospitalization for hematopoietic stem cell transplantation (HCT) on the quality of life (QOL) and mood of patients and family caregivers (FC).


Oncologist | 2017

Effects of Early Integrated Palliative Care on Caregivers of Patients with Lung and Gastrointestinal Cancer: A Randomized Clinical Trial

Areej El-Jawahri; Joseph A. Greer; William F. Pirl; Elyse R. Park; Vicki A. Jackson; Anthony L. Back; Mihir M. Kamdar; Juliet Jacobsen; Eva Chittenden; Simone Rinaldi; Emily R. Gallagher; Justin Eusebio; Sarah Fishman; Harry VanDusen; Zhigang Li; Alona Muzikansky; Jennifer S. Temel

This article reports a single‐center randomized clinical trial that evaluated the effect of early integrated specialty palliative care on patient‐ and caregiver‐reported outcomes in patients with newly‐diagnosed, incurable cancers. It was hypothesized that caregivers of patients assigned to early integrated palliative care would report lower psychological distress and better quality of life compared with caregivers of patients assigned to usual oncology care.


Bone Marrow Transplantation | 2015

Prognostic Understanding, Quality of Life, and Mood in Patients Undergoing Hematopoietic Stem Cell Transplantation

Areej El-Jawahri; Lara Traeger; Kailyn Kuzmuk; Justin Eusebio; Harry VanDusen; Tanya Keenan; Jennifer H. Shin; Emily R. Gallagher; Joseph A. Greer; William F. Pirl; Vicki A. Jackson; Karen K. Ballen; Thomas R. Spitzer; Timothy A. Graubert; Steven L. McAfee; Bimalangshu R. Dey; Yi-Bin Chen; Jennifer S. Temel

Little is known about how patients undergoing hematopoietic stem cell transplantation (HCT) and their family caregivers (FC) perceive their prognosis. We examined prognostic understanding in patients undergoing HCT and their FC and its relationship with quality of life (QOL) and mood. We conducted a longitudinal study of patients (and FC) hospitalized for HCT. We used a questionnaire to measure participants’ prognostic understanding and asked the oncologists to estimate patients’ prognosis prior to HCT. We assessed QOL and mood weekly and evaluated the relationship between prognostic understanding, and QOL and mood using multivariable linear mixed models. We enrolled 90 patients undergoing (autologous (n=30), myeloablative (n=30) or reduced intensity allogeneic (n=30)) HCT. About 88.9% of patients and 87.1% of FC reported it is ‘extremely’ or ‘very’ important to know about prognosis. However, 77.6% of patients and 71.7% of FC reported a discordance and more optimistic prognostic perception compared to the oncologist (P<0.0001). Patients with a concordant prognostic understanding with their oncologists reported worse QOL (β=−9.4, P=0.01) and greater depression at baseline (β=1.7, P=0.02) and over time ((β=1.2, P<0.0001). Therefore, Interventions are needed to improve prognostic understanding, while providing patients with adequate psychological support.


Journal of Clinical Oncology | 2016

Effect of early integrated palliative care on family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer.

Areej El-Jawahri; Vicki A. Jackson; Joseph A. Greer; William F. Pirl; Elyse R. Park; Anthony L. Back; Alona Muzikansky; Mihir M. Kamdar; Simone Rinaldi; Juliet Jacobsen; Joel Fishbein; Justin Eusebio; Harry VanDusen; Ryan D. Nipp; David P. Ryan; Jennifer S. Temel

234 Background: Patients with newly diagnosed advanced cancers who receive early palliative care (PC) integrated with oncology care report improvement in their quality of life (QOL) and mood. While a telephone-based psycho-educational intervention for FC decrease depression, the impact of early, integrated outpatient PC models on FC outcomes remains unknown. METHODS We conducted a randomized trial of early PC integrated with oncology care versus oncology care alone for newly diagnosed patients with incurable lung and gastrointestinal cancers and their FC. Eligible FC were relatives or friends who would likely accompany the patient to clinic visits. FC were eligible to enroll up to 4 weeks after patient enrollment. The intervention entailed at least monthly patient visits with PC from the time of enrollment. FC were not required to attend these visits. We used the Medical Outcomes Study Health Survey Short Form-36 to examine QOL and the Hospital Anxiety and Depression Scale to examine mood at baseline, weeks 12 and 24. We used the two-sample t-test to examine changes in QOL and mood from baseline to week 12 and week 24. RESULTS We enrolled 350 patients and 275 (78.6%) of potentially eligible FC (control n = 138, intervention n = 137) between 5/2/2011 to 7/20/2015. FC outcomes missing data rate at 12 and 24 weeks were 16.8% and 33.8% respectively. At 12 weeks, FC of patients receiving early PC reported higher vitality (1.1 vs. -3.2, p = 0.05) and social functioning (-3.0 vs. -3.8, p = 0.02), and lower depression symptoms (-0.45 vs. 0.24, p = 0.03) compared to FC of patients assigned to usual care. At 24 weeks, FC of patients assigned to early PC had lower depression symptoms (-0.37 vs. 0.28, p = 0.05), but no differences in vitality or social functioning compared to those receiving usual care. No differences in other SF-36 subscales or anxiety were noted at 12 and 24 weeks. CONCLUSIONS Early involvement of PC for patients with newly diagnosed lung and gastrointestinal cancers leads to improvements in FC depression and aspects of QOL. This work demonstrates that the benefits of early, integrated palliative care models in oncology care extend beyond patient outcomes and positively impact the experience of FC. CLINICAL TRIAL INFORMATION NCT01401907.


Journal of Clinical Oncology | 2016

Randomized trial of inpatient palliative care in patients hospitalized for hematopoietic stem cell transplantation (HCT).

Areej El-Jawahri; Thomas W. LeBlanc; Harry VanDusen; Lara Traeger; Joseph A. Greer; William F. Pirl; Vicki A. Jackson; Jason Telles; Alison Rhodes; Yi-Bin Chen; Jennifer S. Temel

103 Background: During HCT, patients experience physical and psychological symptoms that negatively impact their quality of life (QOL). We assessed the impact of an inpatient palliative care intervention on patient QOL, symptom burden, and mood during HCT hospitalization and at 3 months post-HCT. METHODS We randomized 160 patients with hematologic malignancies admitted for autologous or allogeneic HCT to an inpatient palliative care intervention (n=81) integrated with transplant care compared to transplant care alone (n=79). We used the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) to assess QOL, the Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire (PHQ-9) to assess mood, and Edmonton Symptom Assessment Scale (ESAS) to measure symptoms at baseline, week-2, and 3 months post-HCT. We measured post-traumatic stress (PTSD) symptoms using the PTSD checklist at baseline and 3 months post-HCT. We used linear regression models controlling for baseline values to assess the intervention effects on outcomes at week-2 and 3 months post-HCT. RESULTS Between 8/2014 and 1/2016, we enrolled 160/186 (86%) of potentially eligible patients. At week-2, the intervention led to improvements in QOL, depression, anxiety, and symptom burden. At 3 months post-HCT, the intervention led to improvements in QOL, depression, and PTSD [Table 1]. PHQ-9 scores at week-2 and HADS-anxiety scores at 3 months did not differ significantly. CONCLUSIONS Palliative care improved QOL, depression, anxiety, and symptom burden in patients hospitalized for HCT with notable sustained effects 3 months post-HCT. Involvement of palliative care for patients with hematologic malignancies can improve their outcomes and substantially reduce the morbidity of HCT. CLINICAL TRIAL INFORMATION NCT02207322. [Table: see text].


Oncologist | 2018

Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia

Areej El-Jawahri; Margaret Nelson‐Lowe; Harry VanDusen; Lara Traeger; Gregory A. Abel; Joseph A. Greer; Amir T. Fathi; David P. Steensma; Thomas W. LeBlanc; Zhigang Li; Daniel J. DeAngelo; Martha Wadleigh; Gabriela Hobbs; Julia Foster; Andrew M. Brunner; Philip C. Amrein; Richard Stone; Jennifer S. Temel

Acute myeloid leukemia (AML) in adults aged 60 years and older has a poor prognosis. The goal of this study was to describe the perceptions of older patients with AML regarding treatment decisions and the potential risks and benefits of treatment. Patient‐clinician concordance in estimated treatment risk and the likelihood of cure with intensive and nonintensive treatment was also examined.


Journal of Clinical Oncology | 2015

Qualitative study of patients’ and family caregivers’ (FC) perceptions and information preferences about hospice.

Areej El-Jawahri; Jennifer A. Shin; Lara Traeger; Helen Knight; Kristina Mirabeau-Beale; Joel Fishbein; Harry VanDusen; Tanya Keenan; Vicki A. Jackson; Angelo E. Volandes; Jennifer S. Temel

50 Background: Despite the benefits of hospice for patients with advanced cancer and their FC, many patients are referred late or not at all. To assess potential patient and FC barriers to enrollment, we assessed their perceptions, knowledge, and information preferences about hospice. METHODS We conducted qualitative interviews with 16 adult patients with metastatic cancer and a prognosis ≤ 12 months and 8 of their FC. We used a semi-structured interview guide to elicit their perceptions (including perceived barriers to utilization), knowledge, and information preferences about hospice. Two raters coded interviews independently and reached acceptable inter-rater reliability (κ > 0.85). We used content analysis to identify themes. RESULTS We found similar themes between patients and FC interviews. Participants had mixed views about which patients need hospice with some stating it is for patients only at the end-of-life and others perceiving it as important for patients who need care their family cannot provide. Notably, most patients perceived themselves as not needing hospice in the near future. While the majority perceived the role of hospice to enhance quality of life and provide comfort, some viewed it as providing practical support, including 24-hour care. 50% of participants had positive feelings about hospice, while others were more ambivalent. All participants felt they needed more information about hospice, yet they were mixed regarding the optimal timing of this information. Many thought it would be helpful to have information about hospice through pamphlets, websites, or videos, prior to a discussion with their oncologist. Most viewed denial and hope as the main barriers to early hospice enrollment. CONCLUSIONS Study participants had misunderstandings about which patients were appropriate for hospice and regarding the services offered. Participants expressed strong desires for more information about hospice with educational tools, although were mixed about the optimal timing for reviewing these tools. These findings suggest that patients and FC would benefit from interventions to enhance their understanding of hospice and to facilitate a discussion with their oncologists.


Journal of Clinical Oncology | 2016

Inpatient integrated palliative and transplant care to improve family caregiver (FC) outcomes of patients hospitalized for hematopoietic stem cell transplantation (HCT).

Harry VanDusen; Thomas W. LeBlanc; Lara Traeger; Joseph A. Greer; William F. Pirl; Vicki A. Jackson; Jason Telles; Alison Rhodes; Yi-Bin Chen; Jennifer S. Temel; Areej El-Jawahri


Cancer | 2016

Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation.

Areej El-Jawahri; Harry VanDusen; Lara Traeger; Joel Fishbein; Tanya Keenan; Emily R. Gallagher; Joseph A. Greer; William F. Pirl; Vicki A. Jackson; Thomas R. Spitzer; Yi-Bin Chen; Jennifer S. Temel

Collaboration


Dive into the Harry VanDusen's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge